The design of this study was based on donepezil, a selective acetylcholinesterase (AChE) inhibitor used in the treatment of AD, consisting of an 1-indanone ring and a benzylpiperidine moiety. For this purpose, the 1-indanone ring was replaced with a 2-indolinone ring and new hybrid compounds were designed by connecting the benzylpiperidine residue to the 2-indolinone ring via the thiosemicarbazone bridge. Based on the results of in silico studies, 29 new 2-indolinone benzylpiperidine-thiosemicarbazone hybrid compounds ( 10a-n and 11a-o ) were selected and synthesized. The in vitro anti-cholinesterase (ChE) activities of the compounds were determined and compared with donepezil (IC50 = 0.44 μM for AChE and IC50 = 4.70 μM for BuChE). Compound 11e showed the strongest inhibition (IC50 = 0.91 μM for AChE and IC50 = 30.97 μM for BuChE), while compounds 11a, 11b, 11d, 11g, 11k, 11l and 11n also displayed strong AChE inhibitory activity (range of IC50 = 1.15–3.13 μM). Compounds showed weak or no inhibition against BuChE. The cytotoxic effects of the active compounds were evaluated in HUVEC cell lines, and non-cytotoxic effects were observed for compounds 11b, 11d, 11e and 11k . Neuroprotective effect studies of active and non-cytotoxic compounds in HUVEC cells were performed in SH-SY5Y cells exposed to H2O2-induced damage. According to the results, compounds 11e and 11k exhibited significant neuroprotective effects in damaged SH-SY5Y cells, with the compound 11e showing higher protective effect than compound 11k . Compound 11e exhibited a markedly higher permeability across the blood-brain barrier (BBB) model. Compound 11e was selected as the lead candidate based on mechanistic findings. Molecular dynamics simulation of compound 11e was performed on the AChE binding pocket.
No takes yet. Share an insight, caveat, or question.
Soylu-Eter et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: